Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Robert Andrew Winn

TitleAffiliate - VA
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/315-0011

    Collapse Research 
    Collapse research activities and funding
    K22CA113700     (WINN, ROBERT ANDREW)Sep 14, 2006 - Aug 31, 2010
    NIH/NCI
    The effect of Wnt pathway signaling in NSCLC
    Role: Principal Investigator

    R21CA153268     (WINN, ROBERT ANDREW)Aug 1, 2010 - Jul 31, 2013
    NIH/NCI
    Wnt 7a and Its Role in EMT and Lung Cancer Metastasis
    Role: Principal Investigator

    R01CA138528     (WINN, ROBERT ANDREW)Sep 2, 2010 - Jul 31, 2015
    NIH/NCI
    Role of the noncanonical WNT pathway in non-small cell lung cancer
    Role: Principal Investigator

    I01BX001004     (WINN, ROBERT ANDREW)Apr 1, 2011 - Mar 31, 2015
    VA
    The Wnt and Prostacyclin pathways act in concert to inhibit NSCLC cell growth
    Role: Principal Investigator

    P20CA202908     (WINN, ROBERT ANDREW)Sep 23, 2015 - Aug 31, 2019
    NIH/NCI
    1/2 The GUIDE Cancer Research Training Project
    Role: Principal Investigator

    U54CA202995     (CIECIERSKI, CHRISTINA)Sep 24, 2015 - Aug 31, 2020
    NIH/NCI
    2/3: The Chicago Collaborative to Promote and Advance Cancer Health Equity
    Role: Co-Principal Investigator

    U54CA202997     (WINN, ROBERT ANDREW)Sep 24, 2015 - Aug 31, 2020
    NIH/NCI
    3/3: The Chicago Collaborative to Promote and Advance Cancer Health Equity
    Role: Principal Investigator

    U54CA203000     (SIMON, MELISSA ANDREA)Sep 24, 2015 - Aug 31, 2020
    NIH/NCI
    1/3: The Chicago Collaborative to Promote and Advance Cancer Health Equity
    Role: Co-Principal Investigator

    UG3OD023189     (GREENLAND, PHILIP)Jul 6, 2016 - Jun 30, 2021
    NIH
    Illinois Precision Medicine Consortium (IPMC)
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Watson KS, Blok AC, Buscemi J, Molina Y, Fitzgibbon M, Simon MA, Williams L, Matthews K, Studts JL, Lillie SE, Ostroff JS, Carter-Harris L, Winn RA. Society of Behavioral Medicine supports implementation of high quality lung cancer screening in high-risk populations. Transl Behav Med. 2016 Dec; 6(4):669-671. PMID: 27646803.
      View in: PubMed
    2. Buscemi J, Miguel YS, Tussing-Humphreys L, Watts EA, Fitzgibbon ML, Watson K, Winn RA, Matthews KL, Molina Y. Rationale and design of Mi-CARE: The mile square colorectal cancer screening, awareness and referral and education project. Contemp Clin Trials. 2017 Jan; 52:75-79. PMID: 27888090.
      View in: PubMed
    3. Feldman LE, Pasquinelli M, Alban J, Dudek AZ, Winn R, Watson K, Menchaca MG, Koshy M, Kovitz K. PS01.11: Comparison of Initial (T0) Screens in UI Health's Minority-Based Lung Cancer Screening Program to that of the National Lung Screening Trial (NLST): Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11(11S):S275-S276. PMID: 27969478.
      View in: PubMed
    4. Becker EA, Buscemi J, Fitzgibbon ML, Watson K, Matthews KL, Winn RA. Society of Behavioral Medicine (SBM) position statement: SBM supports the National Colorectal Cancer Roundtable's (NCCRT) call to action to reach 80 % colorectal cancer screening rates by 2018. Transl Behav Med. 2016 Jun; 6(2):306-8. PMID: 27357000.
      View in: PubMed
    5. Sechler M, Borowicz S, Van Scoyk M, Avasarala S, Zerayesus S, Edwards MG, Kumar Karuppusamy Rathinam M, Zhao X, Wu PY, Tang K, Bikkavilli RK, Winn RA. Novel Role for ?-Catenin in the Regulation of Cancer Cell Migration via the Induction of Hepatocyte Growth Factor Activator Inhibitor Type 1 (HAI-1). J Biol Chem. 2015 Jun 19; 290(25):15610-20. PMID: 25925948.
      View in: PubMed
    6. Avasarala S, Van Scoyk M, Karuppusamy Rathinam MK, Zerayesus S, Zhao X, Zhang W, Pergande MR, Borgia JA, DeGregori J, Port JD, Winn RA, Bikkavilli RK. PRMT1 Is a Novel Regulator of Epithelial-Mesenchymal-Transition in Non-small Cell Lung Cancer. J Biol Chem. 2015 May 22; 290(21):13479-89. PMID: 25847239.
      View in: PubMed
    7. Borowicz S, Van Scoyk M, Avasarala S, Karuppusamy Rathinam MK, Tauler J, Bikkavilli RK, Winn RA. The soft agar colony formation assay. J Vis Exp. 2014 Oct 27; (92):e51998. PMID: 25408172.
      View in: PubMed
    8. Bikkavilli RK, Avasarala S, Van Scoyk M, Karuppusamy Rathinam MK, Tauler J, Borowicz S, Winn RA. In vitro methylation assay to study protein arginine methylation. J Vis Exp. 2014 Oct 05; (92):e51997. PMID: 25350748.
      View in: PubMed
    9. Gardeux V, Achour I, Li J, Maienschein-Cline M, Li H, Pesce L, Parinandi G, Bahroos N, Winn R, Foster I, Garcia JG, Lussier YA. 'N-of-1-pathways' unveils personal deregulated mechanisms from a single pair of RNA-Seq samples: towards precision medicine. J Am Med Inform Assoc. 2014 Nov-Dec; 21(6):1015-25. PMID: 25301808.
      View in: PubMed
    10. Avasarala S, Bikkavilli RK, Van Scoyk M, Zhang W, Lapite A, Hostetter L, Byers JT, Heasley LE, Sohn JW, Winn RA. Heterotrimeric G-protein, Ga16, is a critical downstream effector of non-canonical Wnt signaling and a potent inhibitor of transformed cell growth in non small cell lung cancer. PLoS One. 2013; 8(10):e76895. PMID: 24204697.
      View in: PubMed
    11. Spreafico A, Tentler JJ, Pitts TM, Tan AC, Gregory MA, Arcaroli JJ, Klauck PJ, McManus MC, Hansen RJ, Kim J, Micel LN, Selby HM, Newton TP, McPhillips KL, Gustafson DL, Degregori JV, Messersmith WA, Winn RA, Eckhardt SG. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clin Cancer Res. 2013 Aug 01; 19(15):4149-62. PMID: 23757356.
      View in: PubMed
    12. Avasarala S, Van Scoyk M, Wang J, Sechler M, Vandervest K, Brzezinski C, Weekes C, Edwards MG, Arcaroli J, Davis RE, Bikkavilli RK, Winn RA. hsa-miR29b, a critical downstream target of non-canonical Wnt signaling, plays an anti-proliferative role in non-small cell lung cancer cells via targeting MDM2 expression. Biol Open. 2013 Jul 15; 2(7):675-85. PMID: 23862015.
      View in: PubMed
    13. Sechler M, Cizmic AD, Avasarala S, Van Scoyk M, Brzezinski C, Kelley N, Bikkavilli RK, Winn RA. Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies. Pharmgenomics Pers Med. 2013; 6:25-36. PMID: 23690695.
      View in: PubMed
    14. Bikkavilli RK, Avasarala S, Vanscoyk M, Sechler M, Kelley N, Malbon CC, Winn RA. Dishevelled3 is a novel arginine methyl transferase substrate. Sci Rep. 2012; 2:805. PMID: 23150776.
      View in: PubMed
    15. Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn RA, Hidalgo M. Stromal cell-derived factor 1a mediates resistance to mTOR-directed therapy in pancreatic cancer. Neoplasia. 2012 Aug; 14(8):690-701. PMID: 22952422.
      View in: PubMed
    16. Tennis MA, Vanscoyk MM, Wilson LA, Kelley N, Winn RA. Methylation of Wnt7a is modulated by DNMT1 and cigarette smoke condensate in non-small cell lung cancer. PLoS One. 2012; 7(3):e32921. PMID: 22403725.
      View in: PubMed
    17. Weekes CD, Winn RA. The many faces of wnt and pancreatic ductal adenocarcinoma oncogenesis. Cancers (Basel). 2011 Sep 21; 3(3):3676-86. PMID: 24212973.
      View in: PubMed
    18. Winn RA, Tuder RM. "Un-slugging" resistance to epidermal growth factor receptor inhibition. A positive outlook for the future of lung cancer therapy. Am J Respir Crit Care Med. 2011 Apr 15; 183(8):970-2. PMID: 21498821.
      View in: PubMed
    19. Mueller SW, Winn R, Macht M, Fish DN, Kiser TH, MacLaren R. Neuromuscular blockade resistance during therapeutic hypothermia. Ann Pharmacother. 2011 Mar; 45(3):e15. PMID: 21386017.
      View in: PubMed
    20. Tennis MA, Van Scoyk MM, Freeman SV, Vandervest KM, Nemenoff RA, Winn RA. Sprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial-mesenchymal transition, and is regulated by Wnt7A through PPARgamma in non-small cell lung cancer. Mol Cancer Res. 2010 Jun; 8(6):833-43. PMID: 20501643.
      View in: PubMed
    21. Tennis MA, Van Scoyk M, Heasley LE, Vandervest K, Weiser-Evans M, Freeman S, Keith RL, Simpson P, Nemenoff RA, Winn RA. Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1. Neoplasia. 2010 Mar; 12(3):244-53. PMID: 20234818.
      View in: PubMed
    22. Choudhary R, Li H, Winn RA, Sorenson AL, Weiser-Evans MC, Nemenoff RA. Peroxisome proliferator-activated receptor-gamma inhibits transformed growth of non-small cell lung cancer cells through selective suppression of Snail. Neoplasia. 2010 Mar; 12(3):224-34. PMID: 20234816.
      View in: PubMed
    23. Tennis MA, Vanscoyk M, Keith RL, Winn RA. The role of prostacyclin in lung cancer. Transl Res. 2010 Feb; 155(2):57-61. PMID: 20129485.
      View in: PubMed
    24. Weiser-Evans MC, Wang XQ, Amin J, Van Putten V, Choudhary R, Winn RA, Scheinman R, Simpson P, Geraci MW, Nemenoff RA. Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against lung cancer progression and metastasis. Cancer Res. 2009 Mar 01; 69(5):1733-8. PMID: 19208832.
      View in: PubMed
    25. Wang XQ, Li H, Van Putten V, Winn RA, Heasley LE, Nemenoff RA. Oncogenic K-Ras regulates proliferation and cell junctions in lung epithelial cells through induction of cyclooxygenase-2 and activation of metalloproteinase-9. Mol Biol Cell. 2009 Feb; 20(3):791-800. PMID: 19037103.
      View in: PubMed
    26. Nemenoff R, Meyer AM, Hudish TM, Mozer AB, Snee A, Narumiya S, Stearman RS, Winn RA, Weiser-Evans M, Geraci MW, Keith RL. Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator--activated receptor gamma. Cancer Prev Res (Phila). 2008 Oct; 1(5):349-56. PMID: 19138979.
      View in: PubMed
    27. Rai PR, Cool CD, King JA, Stevens T, Burns N, Winn RA, Kasper M, Voelkel NF. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008 Sep 15; 178(6):558-64. PMID: 18556624.
      View in: PubMed
    28. Van Scoyk M, Randall J, Sergew A, Williams LM, Tennis M, Winn RA. Wnt signaling pathway and lung disease. Transl Res. 2008 Apr; 151(4):175-80. PMID: 18355764.
      View in: PubMed
    29. Nemenoff RA, Weiser-Evans M, Winn RA. Activation and Molecular Targets of Peroxisome Proliferator-Activated Receptor-gamma Ligands in Lung Cancer. PPAR Res. 2008; 2008:156875. PMID: 18509496.
      View in: PubMed
    30. Heasley LE, Winn RA. Analysis of Wnt7a-stimulated JNK activity and cJun phosphorylation in non-small cell lung cancer cells. Methods Mol Biol. 2008; 468:187-96. PMID: 19099255.
      View in: PubMed
    31. Bren-Mattison Y, Meyer AM, Van Putten V, Li H, Kuhn K, Stearman R, Weiser-Evans M, Winn RA, Heasley LE, Nemenoff RA. Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol. 2008 Mar; 73(3):709-17. PMID: 18055759.
      View in: PubMed
    32. Tennis M, Van Scoyk M, Winn RA. Role of the wnt signaling pathway and lung cancer. J Thorac Oncol. 2007 Oct; 2(10):889-92. PMID: 17909349.
      View in: PubMed
    33. Winn RA, Van Scoyk M, Hammond M, Rodriguez K, Crossno JT, Heasley LE, Nemenoff RA. Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma. J Biol Chem. 2006 Sep 15; 281(37):26943-50. PMID: 16835228.
      View in: PubMed
    34. Amura CR, Marek L, Winn RA, Heasley LE. Inhibited neurogenesis in JNK1-deficient embryonic stem cells. Mol Cell Biol. 2005 Dec; 25(24):10791-802. PMID: 16314504.
      View in: PubMed
    35. Douglas IS, Diaz del Valle F, Winn RA, Voelkel NF. Beta-catenin in the fibroproliferative response to acute lung injury. Am J Respir Cell Mol Biol. 2006 Mar; 34(3):274-85. PMID: 16272459.
      View in: PubMed
    36. Rovin RA, Winn R. Pokemon expression in malignant glioma: an application of bioinformatics methods. Neurosurg Focus. 2005 Oct 15; 19(4):E8. PMID: 16241110.
      View in: PubMed
    37. Nemenoff RA, Winn RA. Role of nuclear receptors in lung tumourigenesis. Eur J Cancer. 2005 Nov; 41(16):2561-8. PMID: 16199155.
      View in: PubMed
    38. Chmura K, Chan ED, Noone PG, Zariwala M, Winn RA, Knowles MR, Iseman MD, Gardner EM. A middle-aged woman with recurrent respiratory infections. Respiration. 2005 Jul-Aug; 72(4):427-30. PMID: 16088289.
      View in: PubMed
    39. Bren-Mattison Y, Van Putten V, Chan D, Winn R, Geraci MW, Nemenoff RA. Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene. 2005 Feb 17; 24(8):1412-22. PMID: 15608671.
      View in: PubMed
    40. Winn RA, Marek L, Han SY, Rodriguez K, Rodriguez N, Hammond M, Van Scoyk M, Acosta H, Mirus J, Barry N, Bren-Mattison Y, Van Raay TJ, Nemenoff RA, Heasley LE. Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. J Biol Chem. 2005 May 20; 280(20):19625-34. PMID: 15705594.
      View in: PubMed
    41. Winn RA, Chan ED, Langmack EL, Kotaru C, Aronsen E. Dysphagia, chest pain, and refractory asthma in a 42-year-old woman. Chest. 2004 Nov; 126(5):1694-7. PMID: 15539746.
      View in: PubMed
    42. Winn RA, Heasley LE. Gamma-catenin expression is reduced or absent in a subset of human non-small cell lung cancers, and its re-expression inhibits cell growth. Chest. 2004 May; 125(5 Suppl):122S-3S. PMID: 15136458.
      View in: PubMed
    43. Wick M, Hurteau G, Dessev C, Chan D, Geraci MW, Winn RA, Heasley LE, Nemenoff RA. Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol. 2002 Nov; 62(5):1207-14. PMID: 12391285.
      View in: PubMed
    44. Winn RA, Stoeckli TC, Wilson ML, Burman W, Schwarz MI, Chan ED. Multiple pulmonary nodules in an HIV-positive man on highly active antiretroviral therapy. Chest. 2002 Nov; 122(5):1840-3. PMID: 12426290.
      View in: PubMed
    45. Winn RA, Bremnes RM, Bemis L, Franklin WA, Miller YE, Cool C, Heasley LE. gamma-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene. 2002 Oct 24; 21(49):7497-506. PMID: 12386812.
      View in: PubMed
    Winn's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)